Targeting RNA N6-methyladenosine Modification-- a Novel Therapeutic Target for HER2- Positive Gastric Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Jul 5

PMID 38966068

Authors

Lijun Jia

Di Zhang

Xiaoman Zeng

Li Wu

Xiaowei Tian

Na Xing

Affiliations

Soon will be listed here.

Abstract

Gastric cancer is one of the most common cancers and is considered the 5 most frequent occurring cancer worldwide. It has gained great attention from the clinicians and researchers because of high mortality rate. It is generally treated with chemotherapy, radiotherapy, and surgery. Recently, additional treatment options including immunotherapy and targeted therapy and immunotherapy have been developed. However, poor prognosis, limited survival rate of patients, and drug resistance to treatment remain critical problems. To improve treatment options or to overcome the bottleneck of treatment, identification of diagnostic and prognostic markers, determining the most effective therapeutic options, and uncovering the molecular regulations associated with treatment strategies are required. In this regard n-methyladenosine (m6A) regulation is considered important. This reversible modification plays a crucial role in progression, development and treatment of -positive gastric cancer. Here, we discuss the role of m6A modification in -positive gastric cancer progression through collecting related studies at present. We further discuss the association of m6A modification with therapeutic efficacy in -positive gastric cancer and list some examples. We conclude that modification of m6A can be a new strategy for improving the prognosis and survival rate of -positive gastric cancer patients.

Citing Articles

A New Medical Evaluation for Gastric Cancer Patients to Increase the Success Rate of Immunotherapy: A 2024 Update.

Samasca G, Burz C, Pintea I, Muntean A, Deleanu D, Lupan I Pharmaceuticals (Basel). 2024; 17(9).

PMID: 39338286 PMC: 11435362. DOI: 10.3390/ph17091121.

References

Zhang B, Han L, Tang Y, Zhang G, Fan X, Zhang J . METTL14 regulates M6A methylation-modified primary miR-19a to promote cardiovascular endothelial cell proliferation and invasion. Eur Rev Med Pharmacol Sci. 2020; 24(12):7015-7023. DOI: 10.26355/eurrev_202006_21694. View

Zhang Y, Li L, Ye Z, Zhang L, Yao N, Gai L . Identification of m6A methyltransferase-related genes predicts prognosis and immune infiltrates in head and neck squamous cell carcinoma. Ann Transl Med. 2021; 9(20):1554. PMC: 8576668. DOI: 10.21037/atm-21-4712. View

Li G, Fu Q, Liu C, Peng Y, Gong J, Li S . The regulatory role of N6-methyladenosine RNA modification in gastric cancer: Molecular mechanisms and potential therapeutic targets. Front Oncol. 2022; 12:1074307. PMC: 9763625. DOI: 10.3389/fonc.2022.1074307. View

Ban Y, Tan P, Cai J, Li J, Hu M, Zhou Y . LNCAROD is stabilized by m6A methylation and promotes cancer progression via forming a ternary complex with HSPA1A and YBX1 in head and neck squamous cell carcinoma. Mol Oncol. 2020; 14(6):1282-1296. PMC: 7266281. DOI: 10.1002/1878-0261.12676. View

Lin J, Lian N, Gao Y, Zheng Q, Yang Y, Ma Y . m6A methylation mediates LHPP acetylation as a tumour aerobic glycolysis suppressor to improve the prognosis of gastric cancer. Cell Death Dis. 2022; 13(5):463. PMC: 9107493. DOI: 10.1038/s41419-022-04859-w. View

Luserna di Rora A, Beeharry N, Imbrogno E, Ferrari A, Robustelli V, Righi S . Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia. J Hematol Oncol. 2018; 11(1):99. PMC: 6090987. DOI: 10.1186/s13045-018-0641-1. View

Tang B, Yang Y, Kang M, Wang Y, Wang Y, Bi Y . mA demethylase ALKBH5 inhibits pancreatic cancer tumorigenesis by decreasing WIF-1 RNA methylation and mediating Wnt signaling. Mol Cancer. 2020; 19(1):3. PMC: 6943907. DOI: 10.1186/s12943-019-1128-6. View

Deng L, Deng W, Fan S, Chen M, Qi M, Lyu W . m6A modification: recent advances, anticancer targeted drug discovery and beyond. Mol Cancer. 2022; 21(1):52. PMC: 8842557. DOI: 10.1186/s12943-022-01510-2. View

Malacrida A, Rivara M, Di Domizio A, Cislaghi G, Miloso M, Zuliani V . 3D proteome-wide scale screening and activity evaluation of a new ALKBH5 inhibitor in U87 glioblastoma cell line. Bioorg Med Chem. 2020; 28(4):115300. DOI: 10.1016/j.bmc.2019.115300. View

10.

Xia R, Yao D, Cai X, Xu X . LHPP-Mediated Histidine Dephosphorylation Suppresses the Self-Renewal of Mouse Embryonic Stem Cells. Front Cell Dev Biol. 2021; 9:638815. PMC: 8007871. DOI: 10.3389/fcell.2021.638815. View

11.

Luserna di Rora A, Cerchione C, Martinelli G, Simonetti G . A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target. J Hematol Oncol. 2020; 13(1):126. PMC: 7507691. DOI: 10.1186/s13045-020-00959-2. View

12.

Wong H, Leung R, Kwong A, Chiu J, Liang R, Swanton C . Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2⁺ metastatic breast cancer. Oncologist. 2011; 16(11):1535-46. PMC: 3233287. DOI: 10.1634/theoncologist.2011-0165. View

13.

Cristescu R, Lee J, Nebozhyn M, Kim K, Ting J, Wong S . Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015; 21(5):449-56. DOI: 10.1038/nm.3850. View

14.

Zhang C, Zhang M, Ge S, Huang W, Lin X, Gao J . Reduced m6A modification predicts malignant phenotypes and augmented Wnt/PI3K-Akt signaling in gastric cancer. Cancer Med. 2019; 8(10):4766-4781. PMC: 6712480. DOI: 10.1002/cam4.2360. View

15.

Zhou Y, Zhu S, Cai C, Yuan P, Li C, Huang Y . High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells. Nature. 2014; 509(7501):487-91. DOI: 10.1038/nature13166. View

16.

Chae Y, Kim J . Cancer stem cell metabolism: target for cancer therapy. BMB Rep. 2018; 51(7):319-326. PMC: 6089865. DOI: 10.5483/bmbrep.2018.51.7.112. View

17.

Zhou K, Parisien M, Dai Q, Liu N, Diatchenko L, Sachleben J . N(6)-Methyladenosine Modification in a Long Noncoding RNA Hairpin Predisposes Its Conformation to Protein Binding. J Mol Biol. 2015; 428(5 Pt A):822-833. PMC: 4779075. DOI: 10.1016/j.jmb.2015.08.021. View

18.

Dieci M, Prat A, Tagliafico E, Pare L, Ficarra G, Bisagni G . Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. Ann Oncol. 2016; 27(10):1867-73. DOI: 10.1093/annonc/mdw262. View

19.

Yi Y, Chen X, Zhang J, Zhu J . Novel insights into the interplay between mA modification and noncoding RNAs in cancer. Mol Cancer. 2020; 19(1):121. PMC: 7412851. DOI: 10.1186/s12943-020-01233-2. View

20.

Pai S, Yadav V, Kuo K, Pikatan N, Lin C, Chien M . PDK1 Inhibitor BX795 Improves Cisplatin and Radio-Efficacy in Oral Squamous Cell Carcinoma by Downregulating the PDK1/CD47/Akt-Mediated Glycolysis Signaling Pathway. Int J Mol Sci. 2021; 22(21). PMC: 8584253. DOI: 10.3390/ijms222111492. View